German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults
NCT ID: NCT00199017
Last Updated: 2010-08-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
75 participants
INTERVENTIONAL
2004-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults
NCT00199082
Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma
NCT00499018
Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients
NCT01056679
Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP
NCT00725231
Treatment of Aggressive Localized Lymphoma
NCT00841945
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dexamethasone/Prednisolone
Cyclophosphamide
Vincristine
Daunorubicin
Asparaginase
G-CSF
Mercaptopurine
Cytarabine
Methotrexate
VP16
Vindesine
Adriamycin
Thioguanine
HDARAC
CNS irradiation
Mediastinal irradiation
Cladribine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 15-65 years (55-65 years if biologically younger)
* Written informed consent
Exclusion Criteria
* T-LBL as second malignancy or other active second malignancy
* Cytostatic pretreatment of LBL (exception of emergency treatments)
* Pregnancy
* Severe psychiatric illness or other circumstances which may compromise cooperation of the patient or informed consent
* Participation in other study interfering with study treatment
15 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Johann Wolfgang Goethe University Hospital
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dieter Hoelzer, MD, PhD
Role: STUDY_CHAIR
University Hospital Frankfurt, Medical Dept. II
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital, Medical Dept. II
Frankfurt, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
German Leukemia Trial Registry
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GMALL04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.